BRIDGING THE GAP BETWEEN SCIENCE AND PATIENTS

2 to 4 novel antibiotics by 2030

The growing threat of AMR

The world is losing its most powerful tool in healthcare: antibiotics.

The reason: rapidly rising antibiotic-resistant infections – also called antimicrobial resistance, or AMR.

These infections can affect anyone, of any age, in any country. AMR is a universal issue that impacts us all – we are all at risk.

Antibiotic resistance undermines every aspect of medicine today. We rely on the availability of effective antibiotics to be able to do everything from wisdom tooth extractions to organ transplantation to cancer chemotherapy.

The fragile antibiotic pipeline is close to collapse

Despite the huge societal costs of AMR, there is no viable market for new antibiotics and therefore little funding available to support clinical research.

As a result, important antibiotics in the early stages of development may never get over the “valley of death” to reach patients.

Bridging the gap

Billion

The ground-breaking AMR Action Fund expects to invest more than US$1 billion to bridge the funding gap and respond to the AMR threat.

2-4

New Antibiotics

The Fund aims to bring 2-4 new antibiotics to market this decade that will save patient lives.

The concept of the AMR Action Fund has been developed in collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust. It aims to overcome key technical and funding barriers of late-stage antibiotic development and will work with governments to ensure there is a sustainable pipeline of new antibiotics to fight superbugs.

Together, we must act now to safeguard our future from this global threat.

Our Investors

View Website

AMR is a slow tsunami that threatens to undo a century of medical progress. I very much welcome this new engagement of the private sector in the development of urgently-needed antibacterial treatments. WHO looks forward to working with the AMR Action Fund to accelerate research to address this public health crisis.

— Dr Tedros Adhanom Ghebreyesus

Director General World Health Organization

EIB is actively supporting identified market failures with innovative financial instruments, antimicrobial resistance is clearly one. We welcome the opportunity to join forces with public and private actors, such as the pharmaceutical industry, philanthropic funders, multilateral development banks, and the World Health Organization to tackle this threat. The initiative is aligned with the EIB’s core objectives in health and we are proud to be part of the origination group of the new AMR Action Fund.

— Werner Hoyer

President, European Investment Bank

My 18-month-old son Simon woke up one morning screaming in agony. Within 24 hours, he died from a drug-resistant infection that doctors were powerless to stop. Had effective antibiotics been available, he would still be with us today. For the first time in years, there is real hope on the horizon. The fund’s investment in new antibiotics will provide funding for the sorts of lifesaving treatments that could have saved my son.

— Everly Macario

Public Health Advocate

An Industry-led Fund

The pharmaceutical industry, in collaboration with the WHO, EIB, and the Wellcome Trust, came together to design the AMR Action Fund. So far, over 20 leading pharmaceutical companies have pledged to invest nearly US$1 billion through the new AMR Action Fund.

The AMR Action Fund will bridge innovative candidates in the pipeline through the most challenging later stages of drug development, ultimately providing governments time to make the necessary policy reforms to enable a sustainable antibiotic pipeline.

The AMR Action Fund expects to invest more than US$1 billion with the support of future partners, such as philanthropies, development banks and multilateral organizations. It will form one of the largest collective ventures ever set up to address AMR.

@IFPMA: New #antibiotics and other #antimicrobials deliver unique value to #patients, #healthcare systems and society. The biopharmaceutical industry calls on policymakers to recognize the full value of antibiotics in their valuation systems. #beatAMR➡️https://t.co/ZsX0EKKuxj https://t.co/j3BsLstb5T

- April 6, 2021

@ThomasCueni: An estimated 700,000 people die from #AMR each year, yet little action to address the main market challenges has occurred. The @AMRActionFund will help bridge the funding gap in development of new #antibiotics, but economic policy reforms are still needed: https://t.co/UkoMNw6wBM https://t.co/vLvHZ9b0Uf

- April 6, 2021

@koutterson: Many cancer patients depend on antibiotics https://t.co/JgPww0gbZM

- April 6, 2021

@WeFightAMR: “Antibiotic resistance is like deferred maintenance on a key piece of infrastructure for society,” says @koutterson. The @AMRActionFund and @CARB-X are just some of the organizations working together to bring us more tools to fight rising #AMR.
https://t.co/gR16ie1BSo

- April 6, 2021

@EUjamrai finds policymakers more concerned about access to older AB than development of novel AB. Older AB access challenge addressed by sustainable procurement practices. To fix access, ABs must *exist* in the first place. Pull incentives needed today for innovation tomorrow! https://t.co/WCUP7BBzGk

- April 6, 2021

@OttoCars1: Antibiotics are cornerstones of basic and highly specialized medicine. We need continuous pipeline of novel antibiotics, made available to everyone in need, everywhere ! This reponsibility falls upon governments. https://t.co/qsrGZCtnDI
Join the discussion https://t.co/EzxWZslnuk

- April 6, 2021

BRIDGING THE GAP BETWEEN SCIENCE AND PATIENTS

2 to 4 novel antibiotics by 2030

The growing threat of AMR

The fragile antibiotic pipeline is close to collapse

Bridging the gap

Our Investors

An Industry-led Fund

Stay connected